SNIBE: Easing domestic pressure and overseas recovery support Buy rating

Overview

This report is Goldman Sachs' summary of meeting takeaways after SNIBE participated in the 2026 China Healthcare Corporate Day. The company's IR head, Mr. Yuning Lyu, mainly discussed domestic growth, the impact of Middle East conflict on overseas growth but overall controllability, as well as full-year guidance and the medium- to long-term outlook.

Core views

The core view is positive: domestically, after sharp declines in reagent ASP and pressure on testing volumes in 2025, the environment has improved at the margin in 2026. Domestic reagent revenue is expected to maintain single-digit growth in 2Q26, and the overall domestic business has a chance to return to positive growth. Overseas, most delayed orders from 1Q26 were shipped in April-May, and overseas revenue recovered quickly, with the full-year target still at 15%-20% growth. On valuation, Goldman Sachs believes the company is currently trading below its 5-year average forward P/E, policy risks have suppressed valuation, and the Buy rating remains supported.

Analysis framework

The report is mainly based on company management's communication at the corporate day, tracking domestic policy, testing volume, reagent prices, overseas shipment recovery, regional expansion, and profit structure, and combines a DCF and M&A weighted valuation framework to derive the 12-month target price.

Methodology notes

• Valuation methodDCF/M&A weighted valuation

  The target price consists of 85% DCF value and 15% theoretical M&A value.

  Goldman Sachs gives a 12-month target price of Rmb67, of which 85% comes from a DCF value of Rmb64, based on a 10% discount rate and 2% terminal growth rate; 15% comes from a theoretical M&A value of Rmb84, based on 35x 2026E earnings.

• Fundamental frameworkImport substitution and overseas expansion

  Earnings growth is jointly driven by import substitution in China and international expansion.

  The report expects SNIBE to achieve a 15% earnings CAGR in 2024-2034E, mainly driven by import substitution in China's tier-3 hospitals, share gains after VBP, and expansion in emerging markets and Europe.

• Institutional disclosure frameworkGS Factor Profile

  Goldman Sachs uses four categories of metrics—Growth, Financial Returns, Multiple, and Integrated—to compare the relative attributes of stocks.

  This framework is used to provide investment context and does not directly replace the report's Buy rating and target price, but it helps explain the relative positioning of growth, returns, and valuation.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• SNIBE (300832.SZ)

  Covered company and Buy-rated target

  Strengths

  The company is a fast-growing IVD company based in Shenzhen, focused on CLIA analyzers and reagents; domestic import substitution, market share gains in tier-3 hospitals, and expansion into overseas emerging markets and Europe form the long-term growth drivers.

  Weaknesses

  The domestic business is still affected by reagent pricing, tendering pace, testing volume, and anti-corruption policies; the overseas business is vulnerable in the short term to geopolitical disruptions, logistics, and oil prices.

  Comparison

  The report says the company is currently valued below its 5-year average forward P/E; in overseas markets, its average share is only 3%-4%, and about 6% in India, leaving room for further improvement.

  Risks

  Slower-than-expected progress in import substitution, policy risks such as VBP and DRG/DIP, intensified competition, distributor model risks, and risks from technological evolution.

Key data

• Report date2026-06-29The report was published on 29 June 2026.
• Investment ratingBuyGoldman Sachs states a Buy rating on SNIBE.
• 12-month target priceRmb67The target price is based on 85% DCF value of Rmb64 and 15% theoretical M&A value of Rmb84.
• Current priceRmb42.39The report disclosure section lists SNIBE's price as Rmb42.39.
• 2024-2034E earnings CAGR15%The report expects earnings CAGR to be driven by import substitution in China and international expansion.
• Revenue geographic mixChina 63%, overseas 37%Of the company's current sales revenue, the China market accounts for 63% and overseas markets for 37%.
• Expected 2026 overseas revenue mix45%-50%Management expects overseas revenue to account for 45%-50% of total revenue for full-year 2026.
• Full-year overseas revenue growth target15%-20%Management maintains its full-year overseas revenue year-on-year growth target and expects 2Q26 to return to the target range.
• 1Q26 overseas revenue shortfallRmb70-80mnGeopolitical disruptions and high oil prices caused shipment delays, but most related orders were shipped in April-May.
• April-May overseas revenue growth40%-50% YoYThe shipment of delayed orders drove a rapid recovery in overseas revenue in April-May.
• Emerging market shareAverage 3%-4%; India about 6%Management believes emerging markets will remain the main growth driver over the next 2-3 years.
• Europe overseas revenue share and growth rateAbout one-quarter of overseas revenue; 30%-35% growth in recent yearsEurope is expected to become the next growth driver over the next 3-5 years.
• Potential Europe capacity investmentRmb100-200mn CapExThe company plans a small production base in Europe to improve delivery efficiency and meet localization tender requirements.
• Laboratory service pricing policy scenarioIf implemented in 2H26, reagent ASP may decline by 5%-10%If the policy is delayed, the pricing impact may be pushed back to 2027.

Impact & implications

If domestic testing volumes and reagent prices continue to stabilize, and if the recovery in overseas shipments extends beyond 2Q26, SNIBE's revenue growth and profit structure may improve. A higher mix of high-margin overseas reagents and the higher-priced European market may also support profitability. On valuation, policy risks still suppress market expectations, but the report believes the current valuation, below the 5-year average forward P/E, offers attractiveness.

Risks

• Import substitution progress may be slower than expected.
• Policy risks such as VBP, DRG/DIP, and laboratory service pricing may depress prices or affect the pace of demand.
• Intensified industry competition may affect share, pricing, and margins.
• The distributor model brings risks to channel execution and visibility into end demand.
• The evolution of new technologies may change the competitive landscape in IVD.
• Geopolitical conflict, logistics disruptions, and high oil prices may continue to affect the pace of overseas shipments.

What to watch

• Whether domestic reagent revenue can maintain single-digit growth in 2Q26 and whether the overall domestic business can return to positive growth.
• Whether laboratory service pricing guidelines will be implemented in 2H26, and whether the actual price cuts will be close to the 5%-10% base-case scenario.
• After the recovery in overseas shipments in April-May, whether 2Q26 overseas revenue can return to the full-year growth target range of 15%-20%.
• Whether strong growth in the European market can continue, and progress in penetration of routine testing, high-speed analyzers, and total laboratory automation systems.
• Whether overseas revenue can reach 45%-50% of total revenue in 2026, and whether overseas profit contribution can become broadly balanced with domestic profit contribution.
• The investment progress of the proposed Rmb100-200mn small production base in Europe, the effectiveness of localization tenders, and improvements in delivery efficiency.